Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for non-small cell lung cancer (NSCLC), yet drug resistance remains a major challenge. The interplay between iron metabolism and tumor immunity has garnered increasing attention; however, whether iron ions can modulate ICI efficacy and the underlying molecular mechanisms remain unclear. This study aims to investigate whether iron ions affect PD-L1 expression and the tumor immune microenvironment by activating PLK1 kinase to regulate the NF-κB pathway, and to validate its clinical relevance. We integrated 4D label-free proteomics, in vitro cell models (A549/Calu-3), and an in vivo mouse LLC allograft model. Mechanistic insights were gained through gene knockdown and inhibitor interventions. Additionally, a retrospective analysis of 87 NSCLC patients treated with ICIs was conducted to examine dynamic changes in serum iron levels and perform survival analysis. Proteomic analysis revealed that iron treatment significantly upregulated PLK1 and enriched immune-related pathways, including NF-κB. Experimental validation demonstrated that iron ions inhibit NF-κB p65 (Ser536) phosphorylation via PLK1 upregulation, leading to downregulation of PD-L1 and reprogramming of the cytokine profile (IFN-γ↑, IL-10↓, TNF-α↓). Both in vitro and in vivo experiments confirmed enhanced antitumor efficacy with the combination of iron ions and PD-1 inhibitors. Clinical cohort data showed that an increase in serum iron levels post-treatment was significantly associated with clinical benefit (AUC = 0.7097, P = 0.0016). Moreover, patients in the high-iron group (cut-off value: 1056 µg/L) exhibited significantly longer progression-free survival ( P = 0.0026) and overall survival ( P = 0.0378). To our knowledge, this study identifies the “iron-PLK1-NF-κB” axis as a novel pathway regulating immune checkpoint expression and remodeling the tumor microenvironment. It also suggests that dynamic changes in serum iron levels post-treatment are associated with clinical benefit during ICI therapy. These findings provide a new theoretical foundation and strategic direction for targeting iron metabolism to enhance immunotherapy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: